254 related articles for article (PubMed ID: 17919989)
21. Agalsidase alfa: a review of its use in the management of Fabry disease.
Keating GM
BioDrugs; 2012 Oct; 26(5):335-54. PubMed ID: 22946754
[TBL] [Abstract][Full Text] [Related]
22. The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease - A systematic literature review by a European panel of experts.
Germain DP; Arad M; Burlina A; Elliott PM; Falissard B; Feldt-Rasmussen U; Hilz MJ; Hughes DA; Ortiz A; Wanner C; Weidemann F; Spada M
Mol Genet Metab; 2019 Mar; 126(3):224-235. PubMed ID: 30413388
[TBL] [Abstract][Full Text] [Related]
23. Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial.
Ramaswami U; Bichet DG; Clarke LA; Dostalova G; Fainboim A; Fellgiebel A; Forcelini CM; An Haack K; Hopkin RJ; Mauer M; Najafian B; Scott CR; Shankar SP; Thurberg BL; Tøndel C; Tylki-Szymanska A; Bénichou B; Wijburg FA
Mol Genet Metab; 2019 May; 127(1):86-94. PubMed ID: 30987917
[TBL] [Abstract][Full Text] [Related]
24. The use of agalsidase alfa enzyme replacement therapy in the treatment of Fabry disease.
Morel CF; Clarke JT
Expert Opin Biol Ther; 2009 May; 9(5):631-9. PubMed ID: 19368525
[TBL] [Abstract][Full Text] [Related]
25. Fabry disease in children and response to enzyme replacement therapy: results from the Fabry Outcome Survey.
Ramaswami U; Parini R; Pintos-Morell G; Kalkum G; Kampmann C; Beck M;
Clin Genet; 2012 May; 81(5):485-90. PubMed ID: 21457233
[TBL] [Abstract][Full Text] [Related]
26. Enzyme replacement therapy for Anderson-Fabry disease.
El Dib R; Gomaa H; Carvalho RP; Camargo SE; Bazan R; Barretti P; Barreto FC
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD006663. PubMed ID: 27454104
[TBL] [Abstract][Full Text] [Related]
27. Hearing improvement in patients with Fabry disease treated with agalsidase alfa.
Hajioff D; Goodwin S; Quiney R; Zuckerman J; MacDermot KD; Mehta A
Acta Paediatr Suppl; 2003 Dec; 92(443):28-30; discussion 27. PubMed ID: 14989462
[TBL] [Abstract][Full Text] [Related]
28. Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-Up.
Lenders M; Canaan-Kühl S; Krämer J; Duning T; Reiermann S; Sommer C; Stypmann J; Blaschke D; Üçeyler N; Hense HW; Brand SM; Wanner C; Weidemann F; Brand E
J Am Soc Nephrol; 2016 Mar; 27(3):952-62. PubMed ID: 26185201
[TBL] [Abstract][Full Text] [Related]
29. Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: a pilot study.
Mignani R; Panichi V; Giudicissi A; Taccola D; Boscaro F; Feletti C; Moneti G; Cagnoli L
Kidney Int; 2004 Apr; 65(4):1381-5. PubMed ID: 15086478
[TBL] [Abstract][Full Text] [Related]
30. Effects of enzyme replacement therapy in Fabry disease--a comprehensive review of the medical literature.
Lidove O; West ML; Pintos-Morell G; Reisin R; Nicholls K; Figuera LE; Parini R; Carvalho LR; Kampmann C; Pastores GM; Mehta A
Genet Med; 2010 Nov; 12(11):668-79. PubMed ID: 20962662
[TBL] [Abstract][Full Text] [Related]
31. Enzyme replacement therapy with agalsidase alfa in children with Fabry disease.
Ramaswami U; Wendt S; Pintos-Morell G; Parini R; Whybra C; Leon Leal JA; Santus F; Beck M
Acta Paediatr; 2007 Jan; 96(1):122-7. PubMed ID: 17187618
[TBL] [Abstract][Full Text] [Related]
32. Enzyme replacement therapy stabilizes obstructive pulmonary Fabry disease associated with respiratory globotriaosylceramide storage.
Wang RY; Abe JT; Cohen AH; Wilcox WR
J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S369-74. PubMed ID: 18937048
[TBL] [Abstract][Full Text] [Related]
33. Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey.
Ramaswami U; Whybra C; Parini R; Pintos-Morell G; Mehta A; Sunder-Plassmann G; Widmer U; Beck M;
Acta Paediatr; 2006 Jan; 95(1):86-92. PubMed ID: 16498740
[TBL] [Abstract][Full Text] [Related]
34. Kidney function and 24-hour proteinuria in patients with Fabry disease during 36 months of agalsidase alfa enzyme replacement therapy: a Brazilian experience.
Thofehrn S; Netto C; Cecchin C; Burin M; Matte U; Brustolin S; Nunes AC; Coelho J; Tsao M; Jardim L; Giugliani R; Barros EJ
Ren Fail; 2009; 31(9):773-8. PubMed ID: 19925283
[TBL] [Abstract][Full Text] [Related]
35. Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement.
Pisani A; Spinelli L; Sabbatini M; Andreucci MV; Procaccini D; Abbaterusso C; Pasquali S; Savoldi S; Comotti C; Cianciaruso B
Am J Kidney Dis; 2005 Jul; 46(1):120-7. PubMed ID: 15983965
[TBL] [Abstract][Full Text] [Related]
36. Anderson-Fabry disease in children.
Sestito S; Ceravolo F; Concolino D
Curr Pharm Des; 2013; 19(33):6037-45. PubMed ID: 23448455
[TBL] [Abstract][Full Text] [Related]
37. Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal).
Tsuboi K; Yamamoto H
Genet Med; 2012 Sep; 14(9):779-86. PubMed ID: 22498845
[TBL] [Abstract][Full Text] [Related]
38. Usefulness of tissue Doppler on early detection of cardiac disease in Fabry patients and potential role of enzyme replacement therapy (ERT) for avoiding progression of disease.
Zamorano J; Serra V; Pérez de Isla L; Feltes G; Calli A; Barbado FJ; Torras J; Hernandez S; Herrera J; Herrero JA; Pintos G
Eur J Echocardiogr; 2011 Sep; 12(9):671-7. PubMed ID: 21810826
[TBL] [Abstract][Full Text] [Related]
39. Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature.
Pisani A; Visciano B; Roux GD; Sabbatini M; Porto C; Parenti G; Imbriaco M
Mol Genet Metab; 2012 Nov; 107(3):267-75. PubMed ID: 22963910
[TBL] [Abstract][Full Text] [Related]
40. Effects of Agalsidase Alfa Enzyme Replacement Therapy on Left Ventricular Hypertrophy on Electrocardiogram in a Female Patient with Fabry Disease.
Nakamura K; Morita H; Takaya Y; Saito Y; Miyoshi T; Morinaga H; Sugiyama H; Wada J; Ito H
Int Heart J; 2023 May; 64(3):502-505. PubMed ID: 37197914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
